Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
by on Thursday, April 26th, 2012 | No Comments
Condition: Malignant Melanoma
Intervention: Drug: Zelboraf (vemurafenib)
Sponsors: Genentech; Genentech
Recruiting – verified April 2012
